Does MOSUNETUZUMAB Cause Malignant neoplasm progression? 37 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 37 reports of Malignant neoplasm progression have been filed in association with MOSUNETUZUMAB (Lunsumio Velo). This represents 7.3% of all adverse event reports for MOSUNETUZUMAB.
37
Reports of Malignant neoplasm progression with MOSUNETUZUMAB
7.3%
of all MOSUNETUZUMAB reports
26
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From MOSUNETUZUMAB?
Of the 37 reports, 26 (70.3%) resulted in death, 2 (5.4%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for MOSUNETUZUMAB. However, 37 reports have been filed with the FAERS database.
What Other Side Effects Does MOSUNETUZUMAB Cause?
Cytokine release syndrome (96)
Disease progression (65)
Covid-19 (50)
Neutropenia (39)
Death (38)
Covid-19 pneumonia (37)
Disorientation (31)
Neurological symptom (31)
Vasogenic cerebral oedema (31)
Pneumonia (30)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which MOSUNETUZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
MOSUNETUZUMAB vs MOSUNETUZUMAB-AXGB
MOSUNETUZUMAB vs MOXIFLOXACIN
MOSUNETUZUMAB vs MOXIFLOXACIN\MOXIFLOXACIN
MOSUNETUZUMAB vs MOXONIDINE
MOSUNETUZUMAB vs MS CONTIN